Trifocal IOLs useful for intermediate vision

Article

Two trifocal IOLs enabled patients to have "a useful third focus for intermediate vision", but also resulted in increased background halos and reduced distance visual quality compared with a multifocal IOL, according to new research.

Two trifocal IOLs (AT LISA tri, Carl Zeiss Meditec; FineVision, PhysIOL) enabled patients in whom they were used to have "a useful third focus for intermediate vision," but they also resulted in increased background halos and reduced distance visual quality for users compared with the vision experienced by recipients of two powers (+2.5 D and +3.0 D) of a multifocal IOL (ReSTOR, Alcon), according to new research published in Clinical Ophthalmology. Three of the four authors work for Alcon Research.

The researchers used a Badal optometer and a Snellen visual acuity chart to evaluate all of the implants for resolution, image quality and photic phenomena. They found that resolution equivalent to 20/40 Snellen visual acuity was achieved over almost all of the viewing distance range in those receiving the trifocal implants, but background shadows were more noticeable for those with the trifocal lenses than they were for study participants receiving the multifocal lens.

The authors obtained simulated headlight images using a modulation transfer function (MTF) bench and a 50-μm pinhole target. They determined far, intermediate, and near distance MTF values using vertical and horizontal slits.

The researchers found that distance MTF peaks at 20/20 Snellen–equivalent spatial frequency were greatest for the multifocal IOLs. The near MTF peak with the +2.5 D multifocal IOL occurred at 53 cm and had a 20/20 Snellen–equivalent value; this was lower than the near peaks of the other study lenses but higher than the intermediate foci of both of the trifocal IOLs.

"Based on this laboratory simulation," the authors write, "the ReSTOR +3.0 D is expected to provide high-quality distance and near vision, with a low propensity for halos. The ReSTOR +2.5 D is expected to provide the best distance vision, with low halo intensity and intermediate vision around 50 to 60 cm. The two trifocal IOLs provide improved intermediate vision in the 70 to 80 cm range, although this benefit may come at the expense of increased nighttime halos."

To read the full article, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.